For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Oxaliplatin & Bevacizumab | Bevacizumab and Oxaliplatin: Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes | None | None | 0 | 29 | 15 | 29 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| CONSTIPATION | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDRA (9.0) | View |
| HEARTBURN/DYSPEPSIA | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDRA (9.0) | View |
| TASTE ALTERATION (DYSGEUSIA) | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDRA (9.0) | View |
| VOMITING | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDRA (9.0) | View |
| FEVER (IN THE ABSENCE OF NEUTROPENIA, WHERE NEUTROPENIA IS DEFINED AS ANC <1.0 X 10E9/L) | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (9.0) | View |
| INJECTION SITE REACTION/EXTRAVASATION CHANGES | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (9.0) | View |
| HEMORRHAGE, PULMONARY/UPPER RESPIRATORY - NOSE | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA (9.0) | View |
| ANOREXIA | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | MedDRA (9.0) | View |
| DIZZINESS | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA (9.0) | View |
| NEUROPATHY: SENSORY | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA (9.0) | View |
| MOOD ALTERATION - DEPRESSION | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | MedDRA (9.0) | View |
| PAIN - HEAD/HEADACHE | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (9.0) | View |
| PAIN - ABDOMEN NOS | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDRA (9.0) | View |
| DYSPNEA (SHORTNESS OF BREATH) | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA (9.0) | View |
| PRURITUS/ITCHING | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDRA (9.0) | View |
| HYPERTENSION | SYSTEMATIC_ASSESSMENT | Vascular disorders | MedDRA (9.0) | View |
| NAUSEA | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDRA (9.0) | View |
| FATIGUE (ASTHENIA, LETHARGY, MALAISE) | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (9.0) | View |
| PAIN - OTHER | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (9.0) | View |
| INSOMNIA | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA (9.0) | View |
| COUGH | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA (9.0) | View |